LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

PerkinElmer Inc

Suletud

SektorTervishoid

0

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad

By Trading Economics

Sissetulek

-8.6M

47M

Müük

-21M

699M

P/E

Sektori keskmine

51.072

76.798

Aktsiakasum

1.18

Dividenditootlus

0.28

Kasumimarginaal

6.675

Töötajad

11,000

EBITDA

-14M

181M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+14.93% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.28%

2.37%

Järgmine aktsia dividendi kuupäev (ex-date)

16. jaan 2026

Turustatistika

By TradingEconomics

Turukapital

223M

12B

Eelmine avamishind

0

Eelmine sulgemishind

0

Uudiste sentiment

By Acuity

23%

77%

43 / 374 Pingereas Healthcare

PerkinElmer Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. dets 2025, 23:54 UTC

Kuumad aktsiad

Stocks to Watch: Nike, Cassava Sciences, KB Home

18. dets 2025, 23:51 UTC

Tulu

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18. dets 2025, 23:39 UTC

Suurimad hinnamuutused turgudel

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18. dets 2025, 22:57 UTC

Omandamised, ülevõtmised, äriostud

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18. dets 2025, 21:40 UTC

Tulu

Nike Sales Tick Up, But China Weakness Persists

18. dets 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18. dets 2025, 23:37 UTC

Market Talk
Tulu

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18. dets 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18. dets 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18. dets 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18. dets 2025, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18. dets 2025, 22:59 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18. dets 2025, 22:58 UTC

Omandamised, ülevõtmised, äriostud

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18. dets 2025, 22:57 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18. dets 2025, 22:56 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18. dets 2025, 22:55 UTC

Tulu

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. dets 2025, 21:59 UTC

Tulu

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. dets 2025, 21:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

18. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. dets 2025, 21:35 UTC

Tulu

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18. dets 2025, 21:31 UTC

Tulu

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Greater China Rev Down 17% >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q EPS 53c >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Apparel Rev $3.91B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Equipment Rev $550M >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q N Amer Rev $5.63B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Footwear Rev $7.66B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Greater China Rev $1.42B >NKE

Võrdlus sarnastega

Hinnamuutus

PerkinElmer Inc Prognoos

Hinnasiht

By TipRanks

14.93% tõus

12 kuu keskmine prognoos

Keskmine 111.22 USD  14.93%

Kõrge 123 USD

Madal 100 USD

Põhineb 10 Wall Streeti analüütiku instrumendi PerkinElmer Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

10 ratings

5

Osta

5

Hoia

0

Müü

Sentiment

By Acuity

43 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat